News & events - The MABEL FUND - Market Analysis of Biologics and Biosimilars following Loss of Exclusivity
PDF) Interchangeability of Biosimilars: Overcoming the Final Hurdles
Liese Barbier (@LieseBarbier) / Twitter
Biosimilar Interchangeability Regulatory Practical Considerations
Biosimilars within Haematology & Oncology
PDF) The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
Biosimilars Tendering in Europe: Key Learnings Towards Sustainable Practices
Liese Barbier, Pharm.D. Onderzoeker, KU Leuven, België on Vimeo
Effectively Educating Clinicians and Patients on Biosimilars
Biosimilaire geneesmiddelen in België Standpunt vanuit de reumatologie
Liese Keereman Photography... - Liese Keereman Photography
Liese Barbier - Postdoctoral Researcher - KU Leuven | LinkedIn
Liese Barbier - Biosimilars Nederland
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption | SpringerLink
Liese Barbier - Postdoctoral Researcher - KU Leuven | LinkedIn
Liese Barbier on LinkedIn: Biosimilars
DONALD SINGER: HEALTH, ART AND SCIENCE: European cooperation on healthcare discussed at FPM-HPT conference at Erasmus University in Rotterdam
PhD defence Liese Barbier 4 - The MABEL FUND - Market Analysis of Biologics and Biosimilars following Loss of Exclusivity
Effectively Educating Clinicians And Patients On Biosimilars Across Europe Getting The Right Message Across
Loop | Liese Barbier
Liese Barbier (@LieseBarbier) / Twitter
